New combo therapy shows promise for Tough-to-Treat leukemia
NCT ID NCT02537613
First seen Nov 01, 2025 · Last updated Apr 25, 2026 · Updated 24 times
Summary
This study tested a combination of two drugs, ibrutinib and obinutuzumab, in 54 adults with chronic lymphocytic leukemia (CLL) that had come back or stopped responding to treatment. The main goal was to check safety and find the best doses. Researchers also looked at how well the drugs shrank cancer. This is an early-phase trial, so results help guide future studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Duke University Medical Center
Durham, North Carolina, 27710, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
University of Rochester Wilmot Cancer Inst.
Rochester, New York, 14642, United States
Conditions
Explore the condition pages connected to this study.